1. From Multiplex Serology to Serolomics-A Novel Approach to the Antibody Response against the SARS-CoV-2 Proteome.
- Author
-
Butt J, Murugan R, Hippchen T, Olberg S, van Straaten M, Wardemann H, Stebbins E, Kräusslich HG, Bartenschlager R, Brenner H, Laketa V, Schöttker B, Müller B, Merle U, and Waterboer T
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Viral blood, Antibody Formation, COVID-19 blood, COVID-19 virology, Cohort Studies, Coronavirus Nucleocapsid Proteins genetics, Coronavirus Nucleocapsid Proteins immunology, Enzyme-Linked Immunosorbent Assay, Escherichia coli, Female, HEK293 Cells, Humans, Immunoglobulin A blood, Immunoglobulin G blood, Immunoglobulin M blood, Male, Middle Aged, Open Reading Frames, Pandemics, Phosphoproteins, Proteome immunology, SARS-CoV-2 genetics, Young Adult, Antibodies, Viral immunology, Antigens, Viral immunology, COVID-19 immunology, SARS-CoV-2 immunology
- Abstract
The emerging SARS-CoV-2 pandemic entails an urgent need for specific and sensitive high-throughput serological assays to assess SARS-CoV-2 epidemiology. We, therefore, aimed at developing a fluorescent-bead based SARS-CoV-2 multiplex serology assay for detection of antibody responses to the SARS-CoV-2 proteome. Proteins of the SARS-CoV-2 proteome and protein N of SARS-CoV-1 and common cold Coronaviruses (ccCoVs) were recombinantly expressed in E. coli or HEK293 cells. Assay performance was assessed in a COVID-19 case cohort ( n = 48 hospitalized patients from Heidelberg) as well as n = 85 age- and sex-matched pre-pandemic controls from the ESTHER study. Assay validation included comparison with home-made immunofluorescence and commercial enzyme-linked immunosorbent (ELISA) assays. A sensitivity of 100% (95% CI: 86-100%) was achieved in COVID-19 patients 14 days post symptom onset with dual sero-positivity to SARS-CoV-2 N and the receptor-binding domain of the spike protein. The specificity obtained with this algorithm was 100% (95% CI: 96-100%). Antibody responses to ccCoVs N were abundantly high and did not correlate with those to SARS-CoV-2 N. Inclusion of additional SARS-CoV-2 proteins as well as separate assessment of immunoglobulin (Ig) classes M, A, and G allowed for explorative analyses regarding disease progression and course of antibody response. This newly developed SARS-CoV-2 multiplex serology assay achieved high sensitivity and specificity to determine SARS-CoV-2 sero-positivity. Its high throughput ability allows epidemiologic SARS-CoV-2 research in large population-based studies. Inclusion of additional pathogens into the panel as well as separate assessment of Ig isotypes will furthermore allow addressing research questions beyond SARS-CoV-2 sero-prevalence.
- Published
- 2021
- Full Text
- View/download PDF